Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-01-18
2011-01-18
Romeo, David S (Department: 1647)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C530S333000, C530S333000
Reexamination Certificate
active
07871784
ABSTRACT:
This invention relates to regulation of cell signaling, cell growth, and more particularly to the regulation of cancer or immune cell growth. The invention provides methods of inhibiting interactions between MUC1 and BH3-containing proapoptotic proteins, methods of inhibiting MUC1 expression, and methods of promoting apoptosis. Also provided are screening methods for compounds that inhibit interactions between MUC1 and BH3-containing proapoptotic proteins and pharmaceutical compositions of the same.
REFERENCES:
patent: 4497796 (1985-02-01), Salser et al.
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 4675382 (1987-06-01), Murphy
patent: 4740461 (1988-04-01), Kaufman
patent: 4894227 (1990-01-01), Stevens et al.
patent: 4963484 (1990-10-01), Kufe
patent: 5053489 (1991-10-01), Kufe
patent: 5080898 (1992-01-01), Murphy
patent: 5380712 (1995-01-01), Ballance et al.
patent: 5506343 (1996-04-01), Kufe
patent: 5530101 (1996-06-01), Queen et al.
patent: 5565334 (1996-10-01), Kufe et al.
patent: 5597457 (1997-01-01), Craig et al.
patent: 5612895 (1997-03-01), Balaji et al.
patent: 5766883 (1998-06-01), Ballance et al.
patent: 5776427 (1998-07-01), Thorpe et al.
patent: 5790421 (1998-08-01), Osslund
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5827516 (1998-10-01), Urban et al.
patent: 5861381 (1999-01-01), Chambon et al.
patent: 5874415 (1999-02-01), Kufe et al.
patent: 5965386 (1999-10-01), Kerry-Williams et al.
patent: 5998148 (1999-12-01), Bennett et al.
patent: 6004746 (1999-12-01), Brent et al.
patent: 6020363 (2000-02-01), Hirano et al.
patent: 6054438 (2000-04-01), Taylor-Papadimitriou et al.
patent: 6074841 (2000-06-01), Gearing et al.
patent: 6093573 (2000-07-01), Beamer et al.
patent: 6222020 (2001-04-01), Taylor-Papadimitriou et al.
patent: 6303302 (2001-10-01), Rupp et al.
patent: 6344203 (2002-02-01), Sandrin
patent: 6589921 (2003-07-01), Herrmann et al.
patent: 6716627 (2004-04-01), Dobie
patent: 6716966 (2004-04-01), Madiyalakan et al.
patent: 7147850 (2006-12-01), Madiyalakan
patent: 2002/0110841 (2002-08-01), Kufe
patent: 2003/0235857 (2003-12-01), Rupp et al.
patent: 2004/0018181 (2004-01-01), Kufe et al.
patent: 2004/0166543 (2004-08-01), Kufe
patent: 2004/0209832 (2004-10-01), McSwiggen
patent: 2005/0042209 (2005-02-01), Kufe et al.
patent: 2005/0053606 (2005-03-01), Kufe et al.
patent: 2006/0019256 (2006-01-01), Clarke et al.
patent: 2008/0090770 (2008-04-01), Belmares et al.
patent: 1103623 (1998-07-01), None
patent: WO 93/20841 (1993-10-01), None
patent: WO 96/03502 (1996-02-01), None
patent: WO 99/23114 (1999-05-01), None
patent: WO 91/09867 (1999-07-01), None
patent: WO 00/09744 (2000-02-01), None
patent: WO 00/11206 (2000-03-01), None
patent: WO 00/25827 (2000-05-01), None
patent: WO 00/34468 (2000-06-01), None
patent: WO 00/47763 (2000-08-01), None
patent: WO 00/77031 (2000-12-01), None
patent: WO 01/12217 (2001-02-01), None
patent: WO 01/18035 (2001-03-01), None
patent: WO 01/57068 (2001-08-01), None
patent: WO 02/22685 (2002-03-01), None
patent: WO 02/31512 (2002-04-01), None
patent: WO 02/058450 (2002-08-01), None
patent: WO 03/014303 (2003-02-01), None
patent: WO 03/088995 (2003-10-01), None
patent: WO 2004/044160 (2004-05-01), None
patent: WO 2004/092339 (2004-10-01), None
U.S. Appl. No. 10/486,278, filed Jun. 23, 2004, Reinherz et al.
U.S. Appl. No. 60/308,307, filed Jul. 27, 2001, Kufe.
U.S. Appl. No. 60/502,111, filed Sep. 11, 2003, Jecminek et al.
“MUC-1/X mucin short variant,” GenBank Accession No. AAD10856, dated Jun. 5, 2001.
“MUC-1/Z mucin short variant,” GenBank Accession No. AAD10858, dated Jun. 5, 2001.
“Mucin 1 precursor, non-repetitive splice from Y [validated]—human,” GenBank Accession No. S48146, dated Apr. 20, 2000.
Abe et al., “Characterization of cis-acting elements regulating transcription of the human DF3 breat carcinoma-associated antigen (MUC1) gene,”Proc. Natl. Acad. Sci. USA., 90:282-286, 1993.
Abe et al., “Identification of a family of high molecular weight tumor-associated glycoproteins,”J. Immun., 139:257-261, 1987.
Abe et al., “Sequence Anaylsis of the 5′ region of the human DF3 breast carcinoma-associated antigen gene,”Bio. Biophys. Research Comm., 165:644-649, 1989.
Abe et al., “Sodium butyrate induction of milk-related antigens in human MCF-7 breast carcinoma cells,”Cancer Res., 44:4574-4577, 1984.
Abe et al., “Structural analysis of the DF3 human breat carcinoma-associated protein,”Cancer Res., 49:2834-2839, 1989.
Abe et al., “Transcriptional regulation of DF3 gene expression in human MCF-7 breast carcinoma cells,”J. Cell. Physio., 143:226-231, 1990.
Adams and Cory, “The Bcl-2 Protein Family: Arbiters of Cell Survival,”Science, 281:1322-1326, 1998.
Agrawal and Kandimalla, “Antisense therapeutics: is it as simple as complementary base recognition?”Molecular Medicine Today, 6:72-81, 2000.
Akagi et al., “CA19-9 epitope a possible marker for MUC-1/Y protein,”Int. J. Oncol., 18:1085-1091, 2001.
Alfieri et al., “Activation of heat-shock transcription factor 1 by hypertonic shock in 3T3 cells,”Biochem. J., 319:601-606, 1996.
Apostolopoulos et al., “Production of anti-breast cancer monoclonal antibodies using a glutathione-S-transferase-MUC1 bacterial fusion protein,”British J. Cancer., 67:713-720, 1993.
Arklie et al., “Differentiation antigens expressed by epithelial cells in the lactating breast are also detectable in breast cancers,”Int. J. Cancer, 28:23-29, 1981.
Ashkenazi and Dixit, “Apoptosis control by death and decoy receptors,”Curr. Opin. Cell Biol., 11:255-260, 1999.
Ashkenazi and Dixit, “Death Receptors: Signaling and Modulation,”Science, 281:1305-1308, 1998.
Ashkenazi et al., “Safety and antitumor activity of recombinant soluble Apo2 ligand,”J. Clin. Invest., 104:155-162, 1999.
Backstom et al., “Recombinant MUC1 mucin with a breast cancer-like O-glycosylation produced in large amounts in Chinese-hamster ovary cells,”Biochemical Journal, 376:677-686, 2003.
Banerjee, “Omega amino acids in peptide design: incorporation into helices ,”Biopolymers, 39:769-77, 1996.
Barrett et al., “PLU-1 nuclear protein, which is upregulated in breast cancer, shows restricted expression in normal human adult tissues: a new cancer/testis antigen?,”Int. J. Cancer, 101:581-588, 2002.
Barry and Sharkey, “Observer reproducibility during computer-assisted planimetric measurements of nuclear features,”Hum. Pathol., 16:225-7, 1985.
Barry et al., “Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia,”Biochemical Pharmacology, 40:2353-2362, 1990.
Baruch et al., “Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function,”Int. J. Cancer, 71:741-749, 1997.
Baruch et al., “The breast cancer-associated MUC1 gene generates both a receptor and its cognate binding protein,”Cancer Res., 59:1552-1561, 1999.
Bass, “The short answer,”Nature, 411:428-429, 2001.
Batra et al., “Transfection of the human MUC1 mucin gene into a poorly differentiated human pancreatic tumor cell line, Panc1: integration, expression and ultrastructural changes,”J. Cell Science, 100:841-849, 1991.
Becker et al., “Three-dimensional structure of the Stat3beta homodimer bound to DNA,”Nature, 394:145-151, 1998.
Bellgrau et al., “A role for CD95 ligand in preventing graft rejection,”Nature, 377:630-632, 1995.
Berger et al., “Respiratory carcinoma cell lines: MUC genes and glycoconjugates,”American Journal of Respiratory Cell and Molecular Biology, 20:500-510, 1999.
Bergeron et al., “MAUB is a new mucin antigen associated with bladder cancer,”J. Biol. Chem., 271:6933-6940, 1996.
Beusen et al., “Conformation
Dana-Farber Cancer Institute Inc.
Fulbright & Jaworski
Romeo David S
LandOfFree
Methods and compositions relating to the regulation of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions relating to the regulation of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions relating to the regulation of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2682091